Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 771 9307

Website: ars-pharma.com

Address:

11682 El Camino Real, Suite 300, San Diego, United States

Kouniff56 Aug. 31 at 10:53 PM

$SPRY The ex CMO keeps selling shares , her and husband CEO have 20 M shares together and sold well over 300000 shares in the last weeks ... Showing their support to the new team

1 · Reply

MrBean1234 Aug. 28 at 12:45 PM

$SPRY scripts flat week over week. Around 6 percent market share. One more week of peak season

1 · Reply

omega42 Aug. 27 at 12:15 AM

$SPRY you are looking at the wrong line; cash/investments decreased by alsmost $60M from Q1 and that's what you need to focus on. also what's "proven" how to rip off shareholders, that's probably the only thing they are good at. No wonder co-founder was fired as CEO and new guy is not doing any better

1 · Reply

LTVI Aug. 26 at 10:30 PM

$SPRY @omega42 That’s not cash-burn analysis-you’re treating net loss as cash burn and assuming Q2 spending continues unchanged. Old regime was spending heavily. New regime is pragmatic and strategic. Very simple. New Management already guided to a >40% reduction in cash-based SG&A in H2. $143.8M cash warrants monitoring, but “raise by EOY or bankruptcy” simply isn’t supported by the numbers. $AQST is much more likely to bleed cash while $SPRY becomes profitable.

2 · Reply

omega42 Aug. 26 at 10:10 PM

$SPRY this is SPRY last two Q performance and getting progressively worse. so think about getting acquired, i dont know why anyone would even look at it. they are burning $60M of cash each Q meaning by EOY theyll need to raise, get debt or go bankrupt. very simple

0 · Reply

MrBean1234 Aug. 26 at 7:14 PM

$SPRY low vol but I like the gains. Let’s keep upward TRX momentum

0 · Reply

Stockpsych11 Aug. 26 at 6:22 PM

$SPRY imo, neffy gets acquired by major pharma

4 · Reply

omega42 Aug. 26 at 5:52 PM

$AQST $SPRY - trivia question - who has larger market cap and why? ......I think that market is trying to tell us something and point to winner down the road.

2 · Reply

Mariorx Aug. 26 at 4:52 PM

$SPRY higher lows? Or rug pull

1 · Reply

kibli Aug. 24 at 4:41 PM

$AQST $SPRY Current market caps: AQST 125.51M X $4.67= $586.13M SPRY 99.45M X $5.26= $523.11M

1 · Reply

Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026

Aug 27, 2026, 10:07 AM EDT - 4 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

Aug 21, 2026, 4:41 PM EDT - 10 days ago

SPRY Investors Have Rights – If You Lost Money Investing in ARS Pharmaceuticals Inc. Contact Robbins LLP for Information Recovering Your Losses

Aug 17, 2026, 11:45 AM EDT - 14 days ago

Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026

2026-08-16T14:10:24.000Z - 15 days ago

ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c)

2026-08-16T13:55:12.000Z - 15 days ago

ARS Pharmaceuticals sees cash flow break-even by end of 2027

2026-08-16T13:55:07.000Z - 15 days ago

ARS Pharmaceuticals names Meg Smith as Chief Commercial Officer

Aug 14, 2026, 3:30 PM EDT - 17 days ago

Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026

Aug 13, 2026, 4:30 PM EDT - 18 days ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 18 days ago

ARS Pharmaceuticals Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 18 days ago

ARS Pharmaceuticals Quarterly report: Q2 2026

Aug 13, 2026, 4:01 PM EDT - 18 days ago

ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 7:45 AM EDT - 18 days ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY)

Aug 7, 2026, 6:00 PM EDT - 24 days ago

Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026

Aug 3, 2026, 7:30 AM EDT - 4 weeks ago

ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results

2026-07-07T20:50:12.000Z - 7 weeks ago

ARS Pharmaceuticals announces CEO succession

SNY

Jul 7, 2026, 4:30 PM EDT - 7 weeks ago

ARS Pharmaceuticals Announces CEO Succession

2026-06-24T20:20:29.000Z - 2 months ago

ARS reports no new commercial formulary additions, coverage decisions for neffy

Jun 24, 2026, 4:05 PM EDT - 2 months ago

ARS Pharmaceuticals Provides Commercial and Financial Updates

2026-05-28T13:22:59.000Z - 3 months ago

ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

ARS Pharmaceuticals Quarterly report: Q1 2026

2026-05-15T10:07:53.000Z - 3 months ago

ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)

May 15, 2026, 6:00 AM EDT - 3 months ago

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

May 13, 2026, 8:00 AM EDT - 3 months ago

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

May 7, 2026, 8:00 AM EDT - 4 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

Apr 29, 2026, 8:00 AM EDT - 4 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing

2026-04-15T10:11:10.000Z - 4 months ago

ARS Pharmaceuticals announces Health Canada approval of neffy 2 mg

Apr 15, 2026, 6:05 AM EDT - 4 months ago

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

2026-04-09T11:14:32.000Z - 5 months ago

ARS Pharmaceuticals initiated with an Outperform at Northland

2026-04-09T11:13:02.000Z - 5 months ago

Northland starts disruptor ARS Pharmaceuticals with an Outperform

2026-03-27T12:16:24.000Z - 5 months ago

ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement

Mar 27, 2026, 8:00 AM EDT - 5 months ago

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Mar 11, 2026, 8:00 AM EDT - 6 months ago

ARS Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:30 AM EDT - 6 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 6 months ago

ARS Pharmaceuticals Annual report: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 6 months ago

ARS Pharmaceuticals Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 6 months ago

ARS Pharmaceuticals Slides: Corporate presentation

Mar 9, 2026, 6:00 AM EDT - 6 months ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Feb 23, 2026, 8:00 AM EST - 6 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Feb 10, 2026, 8:00 AM EST - 7 months ago

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 2, 2026, 8:00 AM EST - 7 months ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

Jan 21, 2026, 8:00 AM EST - 7 months ago

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

Dec 29, 2025, 8:00 AM EST - 8 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Dec 3, 2025, 2:30 PM EST - 9 months ago

ARS Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 9 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 10 months ago

ARS Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 6:00 AM EST - 10 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

Nov 4, 2025, 8:00 AM EST - 10 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Nov 3, 2025, 2:23 PM EST - 10 months ago

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Nov 3, 2025, 8:00 AM EST - 10 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Nov 3, 2025, 7:45 AM EST - 10 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 11 months ago

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Sep 29, 2025, 4:05 PM EDT - 1 year ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Sep 17, 2025, 9:00 AM EDT - 1 year ago

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Sep 3, 2025, 3:55 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Aug 4, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Jul 18, 2025, 9:25 AM EDT - 1 year ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Jun 4, 2025, 5:30 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:20 PM EDT - 1 year ago

ARS Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference

Jun 2, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Slides: Corporate Presentation

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 7, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 5, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Kouniff56 Aug. 31 at 10:53 PM

$SPRY The ex CMO keeps selling shares , her and husband CEO have 20 M shares together and sold well over 300000 shares in the last weeks ... Showing their support to the new team

1 · Reply

MrBean1234 Aug. 28 at 12:45 PM

$SPRY scripts flat week over week. Around 6 percent market share. One more week of peak season

1 · Reply

omega42 Aug. 27 at 12:15 AM

1 · Reply

LTVI Aug. 26 at 10:30 PM

2 · Reply

omega42 Aug. 26 at 10:10 PM

0 · Reply

MrBean1234 Aug. 26 at 7:14 PM

$SPRY low vol but I like the gains. Let’s keep upward TRX momentum

0 · Reply

Stockpsych11 Aug. 26 at 6:22 PM

$SPRY imo, neffy gets acquired by major pharma

4 · Reply

omega42 Aug. 26 at 5:52 PM

$AQST $SPRY - trivia question - who has larger market cap and why? ......I think that market is trying to tell us something and point to winner down the road.

2 · Reply

Mariorx Aug. 26 at 4:52 PM

$SPRY higher lows? Or rug pull

1 · Reply

kibli Aug. 24 at 4:41 PM

$AQST $SPRY Current market caps: AQST 125.51M X $4.67= $586.13M SPRY 99.45M X $5.26= $523.11M

1 · Reply

MrBean1234 Aug. 24 at 1:56 PM

$SPRY buying again! Thank you all!

1 · Reply

LTVI Aug. 24 at 12:42 AM

$SPRY https://finance.yahoo.com/healthcare/articles/ars-pharma-spry-cuts-spending-220832511.html

0 · Reply

LTVI Aug. 24 at 12:41 AM

$SPRY bullish.

0 · Reply

LTVI Aug. 24 at 12:41 AM

$SPRY hold?

0 · Reply

LTVI Aug. 24 at 12:41 AM

$SPRY upgrades

0 · Reply

LTVI Aug. 24 at 12:40 AM

$SPRY

0 · Reply

LTVI Aug. 24 at 12:33 AM

$MRK $SNY $SPRY

0 · Reply

omega42 Aug. 23 at 10:47 PM

$SPRY nothing has changes. still same POS

0 · Reply

LTVI Aug. 23 at 6:06 PM

$SPRY $MRK $SNY Fundamentals improving in short order.

0 · Reply

LauraKeating800 Aug. 22 at 3:41 PM

$SPRY $AFRM $DVN $MA $PDD SPRY advances clinical-stage therapies, Affirm benefits from digital payments and consumer credit, Devon Energy remains leveraged to oil and gas prices, Mastercard benefits from global payment volumes, and PDD benefits from Chinese e-commerce demand. I'm watching clinical milestones, credit quality, energy prices, transaction volumes, and Chinese consumption.

0 · Reply

BigGainTom Aug. 21 at 3:04 PM

$SPRY

3 · Reply

BigGainTom Aug. 20 at 11:47 PM

$SPRY https://www.morningstar.com/news/pr-newswire/20260820ny30629/spry-investor-alert-ars-pharmaceuticals-inc-securities-class-action-notice-contact-suewallst

0 · Reply

Market Cap	585.74M
Revenue (ttm)	84.28M
Net Income (ttm)	-171.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-203.25%
Debt to Equity Ratio	13.72

Volume	1,984,600
Avg Vol	2,202,278
Day's Range	N/A - N/A
Shares Out	99.45M
Stochastic %K	50%
Beta	0.98
Analysts	Strong Sell
Price Target	$25.33